METIS TECHBIO-P's stock plummeted 6.56% intraday, with significant trading volume observed during the session.

The decline reflects a continued post-IPO correction following the stock's 173% surge on its debut. The company, which is in early-stage commercialization, has accumulated substantial losses over the past three years with volatile revenue. Additionally, certain international placement shares were not subject to lock-up restrictions, creating persistent profit-taking pressure as early investors exit positions.

METiS is an AI-driven biotech company specializing in targeted drug delivery using its proprietary NanoForge platform, with capabilities for precision delivery across multiple organs and tissues.